VACCINE VIOLENCE: HIB vaccine contains dangerous bacteria that causes serious adverse outcomes post-jab putting 3.5 million U.S. children at risk

Children’s Health Defense (CHD) Chief Scientific Officer Brian Hooker, Ph.D., and Senior Research Scientist Karl Jablonowski, Ph.D., have released a groundbreaking study titled “Adverse outcome detection of childhood administered thimerosal-free HibTITER®,” published in the International Journal of Risk and Safety in Medicine. The paper presents alarming findings that raise serious questions about the safety and regulatory oversight of the HibTITER® vaccine, which was once widely administered to infants across the United States.

• Study Findings: CHD scientists Brian Hooker, Ph.D., and Karl Jablonowski, Ph.D., analyzed Florida Medicaid data (2003–2007) and identified 19 statistically significant adverse health conditions linked to the thimerosal-free HibTITER® vaccine, including pulmonary tuberculosis, asthma, colitis, reflux esophagitis, and gastroenteritis.
• Vaccine Background: The HibTITER® vaccine, manufactured by Wyeth Pharmaceuticals, was used from 1990 to 2007 to protect against Haemophilus influenzae type b (Hib) infections. It was quietly discontinued in 2007, after being administered to an estimated 35 million U.S. infants between 1991 and 2007.
• Safety Concerns: Researchers criticized the limited scope of clinical trials, noting that follow-ups lasted only 72 hours post-vaccination. They argue that rigorous long-term safety studies were never conducted, making the vaccine’s approval and distribution scientifically unjustified.
• Broader Implications: The paper highlights that Hib conjugate vaccines remain experimental, with complex and unstable formulations involving polysaccharides, protein carriers, and adjuvants. The authors warn that continued vaccine experimentation without adequate testing has contributed to rising rates of vaccine-related injuries and chronic illnesses.

Hidden Dangers of the HibTITER® Vaccine: New Research Exposes Serious Health Risks for Millions of Children

The study analyzed a Florida Medicaid dataset containing medical records from January 2003 through June 2007, focusing on adverse outcomes related to HibTITER®, a vaccine developed to protect against Haemophilus influenzae type b (Hib) — a bacterium responsible for severe infections such as meningitis, pneumonia, and sepsis. Despite the vaccine’s intended purpose, the data revealed 19 distinct health conditions, ranging from mild illnesses to life-threatening diseases, that were statistically associated with HibTITER® administration.

During the vaccine’s original clinical trials, safety assessments were limited to phone calls made to caregivers 72 hours after vaccination. Based on these brief follow-ups, researchers declared the vaccine “safe and effective.” However, as Dr. Jablonowski noted, “We were stunned at what the data revealed. This vaccine should have been studied much more intensively before being allowed on the market. In fact, it shouldn’t have ever been allowed to be injected into infants without rigorous safety studies.”

Among the most significant findings of Hooker and Jablonowski’s analysis was a notable increase in pulmonary tuberculosis cases among vaccinated children. Other adverse conditions linked to HibTITER® included asthma, upper respiratory infections, bronchiolitis, otitis media, reflux esophagitis, colitis, enteritis, and gastroenteritis. Many of these outcomes suggest immune and inflammatory dysregulation following vaccination — a signal that the vaccine may have triggered widespread systemic effects in developing children.

The HibTITER® vaccine, produced by Wyeth Pharmaceuticals Inc., was distributed in the U.S. from 1990 until its quiet discontinuation in 2007. Despite the absence of a public recall or safety warning, the vaccine’s removal coincided with rising concerns about vaccine safety and growing reports of adverse events. Dr. Hooker commented, “It is conspicuous that this vaccine was quietly pulled off the market in 2007, especially in light of its relationship to many adverse events in children.”

At its peak, HibTITER® was the dominant Hib vaccine between 1991 and 1994, before sharing the market with other formulations. The researchers estimate that, given the U.S. birth rate and adherence to CDC vaccination schedules, approximately 35 million American children born between 1990 and 2007 may have received the vaccine. These individuals, now between the ages of 16 and 33, could still be living with long-term health consequences linked to their early exposure.

The study also highlights the experimental nature of Hib conjugate vaccines, which rely on complex adjuvants — substances designed to amplify the body’s immune response. The safety of these adjuvants remains poorly understood. In the case of HibTITER®, the conjugation process involved chemically linking Hib polysaccharides to protein carriers through either single-ended or cross-linked methods. However, Hooker and Jablonowski emphasize that neither animal nor human clinical trials have definitively established the safety or long-term efficacy of these conjugate vaccines.

Moreover, the field of vaccine development continues to evolve through increasingly aggressive experimentation in immunology, molecular biology, and glycobiology. While these innovations are often presented as breakthroughs, they have also contributed to what critics describe as a growing epidemic of “vaccine injuries” and “vaccine violence.” The drive to create stronger immune responses — through artificial stimulation and novel adjuvant systems — may be introducing unintended biological consequences, especially in infants and young children whose immune systems are still developing.

The implications of this study are profound. For decades, parents have been assured that vaccines like HibTITER® are both safe and essential, yet this research exposes the lack of long-term safety data and the potential for widespread harm. The findings call for urgent re-evaluation of vaccine approval processes, greater transparency from manufacturers, and independent oversight of vaccine safety data.

In conclusion, the research by Dr. Hooker and Dr. Jablonowski serves as a wake-up call to both the medical community and the public. The HibTITER® vaccine, once administered to millions of infants under government-endorsed programs, may have caused significant harm that went unrecognized for years.

As science continues to uncover the complex interactions between vaccines, the immune system, and long-term health outcomes, it becomes increasingly clear that safety must take precedence over speed and profit. True public health cannot exist without full transparency, rigorous testing, and the ethical responsibility to protect those most vulnerable — our children. Bookmark Infections.news to get the latest updates about the engineered gain of function viruses spread by the eugenicists.

Sources for this article include:

Pandemic.news

NaturalNews.com

SHTFplan.com

ChildrensHealthDefense.org

NIH.gov